Noxxon

Contact
noxxonpharma.com
+4930726247-0

NOXXON Pharma AG

Max-Dohrn-Str. 8-10
10589 Berlin
Germany
+4930726247-0
noxxonpharma.com
Contact
Profile News
Contact

About Noxxon

Berlin-based NOXXON Pharma AG is a clinical stage biotechnology company focusing on the development of Spiegelmers® for the treatment of inflammatory diseases and hematological indications. In addition to its in-house programs NOXXON discovers and develops Spiegelmers® in collaboration with partners from the pharmaceutical industry, including Eli Lilly, Hoffmann La-Roche and Pfizer.

Read more about Noxxon
Facts about Noxxon
  • Focus : Manufacturer
  • Industry : Pharma

News about Noxxon

Noxxon

13-Feb-2017 | people

Industry cancer clinician Dr. Jarl Ulf Jungnelius announced to serve as NOXXON CMO

NOXXON Pharma announced that Jarl Ulf Jungnelius, M.D., Ph.D. will take over the role of Chief Medical Officer. Dr. Jungnelius, who is already familiar ...

Read news
Noxxon

16-Jul-2015 | people

NOXXON appoints Aram Mangasarian as CEO

NOXXON Pharma has appointed Dr. Aram Mangasarian as the new CEO. He is taking over from Iain Buchanan, who will be nominated to join the Supervisory Board ...

Read news
Noxxon

05-Aug-2014 | research and development

NOXXON Initiates Phase IIa Study of Anti-Hepcidin Spiegelmer Lexaptepid Pegol (NOX-H94)

NOXXON Pharma announced the treatment of a first patient with its anti-hepcidin Spiegelmer® lexaptepid pegol (NOX-H94) in a phase IIa proof - of - concept ...

Read news
Noxxon

06-Dec-2012 | research and development

NOXXON Initiates Phase IIa of Anti-Hepcidin Spiegelmer NOX-H94

Anemia of Chronic Disease Study is Fourth Phase II Initiated by NOXXON in 2012

Read news
Noxxon

28-Sep-2012 | research and development

NOXXON Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer

NOX-A12 in Second Oncology Indication: Multiple Myeloma

Read news
Noxxon

13-Jul-2012 | research and development

NOXXON Initiates Phase IIa of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 for Treatment of Chronic Lymphocytic Leukemia

NOXXON Pharma announced the treatment of the first cohort of three chronic lymphocytic leukemia (CLL) patients in a Phase IIa clinical trial of its NOX-A12 ...

Read news
Noxxon

10-Apr-2012 | research and development

NOXXON's NOX-A12 Delays Glioblastoma Recurrence in Preclinical Model

NOXXON Pharma announced that a preclinical study of the SDF-1 inhibiting Spiegelmer NOX-A12 significantly delayed post-irradiation glioblastoma recurrence ...

Read news
Noxxon

14-Dec-2011 | research and development

NOXXON’s SDF-1 inhibitor NOX-A12 completes Phase I

NOXXON Pharma announced the completion of Phase I single and multiple dose clinical trials of its SDF-1 inhibitor NOX-A12. In Phase I studies with healthy ...

Read news
Show more news about Noxxon

Here you will find NOXXON Pharma AG